Accentia Biopharmaceuticals
Advanced Immunotherapeutics
ACCENTIA is a biopharmaceutical company focused on commercialization of innovative products based on revolutionary discoveries in the field of immunology.
Recent News
Sun Jun 28, 2009Personalized Anti-Cancer Vaccine, BiovaxID®, Targeting B-cell Lymphomas Available in Europe on a Named-Patient Basis
Mon May 20, 2009
Personalized Anti-Cancer Vaccine Pivotal Phase III Results to be Presented at ASCO Plenary Session
Media Highlights
BiovaxID® HealthWatch Video: Anti-Cancer Vaccine Breakthrough
ASCO Plenary Session: BiovaxID Phase 3 Results
May 31, 2009
Orlando, FL
Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission (BV301) Phase III clinical trial results
Sunday May 31, 2009:
American Society of Clinical Oncology Annual Meeting (2009), Orlando, FL
Positive, Clinically Significant Phase III Results for Personalized Anti-Cancer Vaccine, BiovaxID®, Presented at ASCO Plenary Session
Redefining the World of Cell Culture
- 20+ Years of Contract Manufacturing Experience
- Innovative Line of Automated Bioreactors
- Superior High Cell Density Production
- Research, Clinical and Commercial Scalability
- Disposable Features for Speed & Ease of Use
- Ideal for MAbs and Personalized Medicines
